Status and phase
Conditions
Treatments
About
A randomized, Phase 2a, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and antiviral activity of multiple doses of orally administered EDP-323 in healthy subjects infected with RSV-A Memphis 37b. This study is designed to assess the antiviral effect of EDP-323 compared to a placebo control in the respiratory syncytial virus challenge model.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
142 participants in 3 patient groups, including a placebo group
Loading...
Central trial contact
Enanta Pharmaceuticals, Inc
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal